On August 4, 2021 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41ST Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time (Press release, Neoleukin Therapeutics, AUG 4, 2021, View Source [SID1234585921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.